References
- Jichlinski P, Guillou L, Karlsen SJ, Malmstrom PU, Jocham D, Brennhovd B, Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer–a multicenter study. J Urol 2003;170:226–9.
- Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010;184:1907–13.
- Riedl CR, Daniltchenko D, Koenig F, Simak R, Loening SA, Pflueger H. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 2001;165:1121–3.
- Hermann GG, Mogensen K, Carlsson S, Marcussen N, Duun S. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in T a/T1 patients: a randomized two-centre study. BJU Int 2011;108:E297–303.
- Loidl W, Schmidbauer J, Susani M, Marberger M. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Eur Urol 2005;47:323–6.
- Witjes JA, Moonen PM, van der Heijden AG. Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study. Eur Urol 2005;47:319–22.
- Sobin LH, Wittekind C. TNM Classification of malignant tumors. 6th ed. Hoboken, NJ: John Wiley & Sons; 2002.
- World Health Organization. WHO classification of tumours. Pathology and genetics. Tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004.
- Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314–30.
- Hermann GG, Horn T, Steven K. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol 1998;159:91–4.
- Beaghler M, Grasso M III. Flexible cystoscopic bladder biopsies: a technique for outpatient evaluation of the lower urinary tract urothelium. Urology 1994;44:756–9.
- Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007;178:62–7.
- Huang GJ, Kim PH, Skinner DG, Stein JP. Outcomes of patients with clinical CIS-only disease treated with radical cystectomy. World J Urol 2009;27:21–5.
- Witjes JA. Bladder carcinoma in situ in 2003: state of the art. Eur Urol 2004;45:142–6.
- Draga ROP, Grimbergen MCM, Kok ET, Jonges TN, Bosch JLHR. Predictors of false positives in 5-aminolevulinic acid-induced photodynamic diagnosis of bladder carcinoma: identification of patient groups that may benefit most from highly specific optical diagnosis. Urology 2009;74:851–7.
- Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828–41.
- Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315–30.